|
|
Vaccine Detail
|
MERS-CoV VLP vaccine |
| Vaccine Information |
- Vaccine Name: MERS-CoV VLP vaccine
- Target Pathogen: MERS-CoV
- Target Disease: Middle East Respiratory Syndrome (MERS)
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: Macaque
- Host Species as Laboratory Animal Model: Rhesus Macaque
- Antigen: MERS-CoV S, E, and M proteins (Wang et al., 2017)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Macaque Response
- Vaccination Protocol: Animals were vaccinated intramuscularly (i.m.) in the gastrocnemius muscle with 250 μg of MERS-CoV VLPs and mixed with 250 μg Alum adjuvant. (Wang et al., 2017)
- Immune Response: Induced neutralizing antibodies (titres up to 1:40), RBD-Specific IgG (endpoint titres up to 1:1,280), T-helper 1 cell (Th1)-mediated immunity, production of IFN-γ. (Wang et al., 2017)
|
| References |
Wang et al., 2017: Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, Feng N, Chi H, Qiu B, Li N, Wang T, Gao Y, Yang S, Xia X. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget. 2017; 8(8); 12686-12694. [PubMed: 27050368].
|
|
